

Communicable Disease Surveillance Centre (CDSC) (2005) Email communication on age distribution of UK plasma donors, May 26, 2005.

Cervenakova L, Brown P, Hammond DJ, Lee CA, Saenko EL.(2002) Factor VIII and transmissible spongiform encephalopathy: the case for safety. *Haemophilia*. Mar;8(2):63-75.

Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. *Transfusion*. 2003 Dec;43(12):1687-94.

CJD Incidents Panel (2004). vCJD and Plasma Products - Recommendations of the CJD Incidents Panel, September 7, 2004.

Det Norske Veritas. Risk Assessment of Exposure to vCJD Infectivity in Blood and Blood Products – for Department of Health. February, 2003. United Kingdom.

Evatt B, Austin H, Barnhart E, Schonberger L, Sharer L, Jones R, DeArmond S. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. *Transfusion*. 1998 Sep;38(9):817-20.

Food and Drug Administration. Guidance for Industry Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. January 2002.

Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC. (2000) Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. *Vox Sang*. 2000;78(2):86-95.

Foster PR.(2004) Removal of TSE agents from blood products. *Vox Sang*. Jul;87 Suppl 2:7-10.

Foster PR, Griffin BD, Bienek C, McIntosh RV, MacGregor IR, Somerville RA, Steele PJ, Reich HE.(2004) Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. *Vox Sang*. Feb;86(2):92-9.

Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, Rohwer RG. (2004). Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. *Lancet* 364(9433): 529-531.

[http://www.hemophilia.org/bdi/bdi\\_types9.htm](http://www.hemophilia.org/bdi/bdi_types9.htm) (accessed Oct 26, 2004).

Health Protection Agency of the United Kingdom, Statistics Unit, Centre for Infections. 2006. Incidence of Variant Creutzfeldt-Jakob Disease Deaths in the UK January 1994 – June 2006 at <http://www.cjd.ed.ac.uk/vcjdqjun06.htm> (accessed August 21, 2006).

Hilton DA, Ghani A, et al. Accumulation of prion protein in tonsil and appendix: review of tissue samples. *BMJ* 2002; 325:633-634.

Hilton DA, Ghani A, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. *J Path* 2004; 203:733-739.

Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. *Lancet* 2000; 356:999-1000.

Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F. Transmission of prion diseases by blood transfusion. *J Gen Virol* 2002; 83:2897-2905.

Ironside JW, Hilton DA, Ghani A, et al. Retrospective study of prion-protein accumulation in tonsil and appendix tissues. *Lancet* 2000; 355: 1693-1694.

Jacquemot C, Cuche C, Dormont D, Lazarini F. High incidence of scrapie induced by repeated injections of subinfectious prion doses 2005; 79:8904-8908.

Kimberlin, R. (1996). Bovine Spongiform Encephalopathy and Public Health: Some Problem and Solutions in Accessing the Risks. Proceedings of the Third international Symposium on Subacute Spongiform Encephalopathies, Paris.

Lee CA, Ironside JW, Bell JE, Giangrande P, Ludlam C, Esiri MM, McLaughlin JE. Retrospective neuropathological review of prion disease in UK haemophilic patients. *Thromb Haemost*. 1998 Dec;80(6):909-11.

Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR Jr. (2001) A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. *Transfusion*. 2001 Apr;41(4):449-55.

Linden JV, Kolakoski MH, Lima JE, Du P, Lipton RA. Factor concentrate usage in persons with hemophilia in New York State. *Transfusion*. 2003 Apr;43(4):470-5.

Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. *Lancet*. 2004 Feb 7;363(9407):417-21.

Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. *Lancet*. 364(9433):527-9.

MESAC Council, 2001

(NBDRC, 2005) The number of annual blood donations is approximately 14,000,000

National Research Council. (1983) Risk Assessment in the Federal Government: Managing the Process. National Academy Press, Washington, DC.

Organization Internationale de Epizootics(OIE) (2005) Table Number of cases of BSE reported in the U.K.. (2006). Data were accessed at [http://www.oie.int/eng/info/en\\_esbru.htm#4](http://www.oie.int/eng/info/en_esbru.htm#4) (Accessed on May 30, 2006).

Plasma Protein Therapeutics Association (2004). Data on the age of US plasma donors was obtained from the Plasma Protein Therapeutics Association(2004). Need more info here

Plasma Protein Therapeutics Association (2005). Information on age distribution of plasma donors provided to FDA

Rohwer, Robert presentation at the Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) Feb 12, 2004. Recent experimental studies in animals regarding TSE infectivity in blood and transfusion transmission of TSE's - Review of recent experiments in rodents and in sheep.

Stenland CJ, Lee DC, Brown P, Petteway SR Jr, Rubenstein R. (2002) Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. *Transfusion*. Nov;42(11):1497-500.

Soucie JM, Evatt B, Jackson D. (1998) Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. *Am J Hematol*. 1998 Dec;59(4):288-94. Transmissible Spongiform Encephalopathies Advisory Committee (FDA-TSEAC), 2000. Presentation by Kevin Watanabe of the American Red Cross.

TaylorDM, Fernie K, Reichl HE, Somerville RA. 2000. Infectivity in the blood of mice with a BSE-derived agent. *J Hosp Infect* 46(1):78-79.

Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC), October 31, 2005. Presentations by FDA staff and discussions by TSEAC on FDA's Risk Assessment for Potential Exposure to Variant Creutzfeldt-Jakob Disease in Human Plasma-Derived Antihemophilic Factor (FVIII) Products.

Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC), 2001. Presentation by Alan Williams, FDA

Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) June 1, 2000. Presentation by K. Watanabe.

United Kingdom National CJD Surveillance Unit - Edinburgh, Scotland, 2006. [<http://www.cjd.ed.ac.U.K./figures.htm>] - Results as of March 31, 2006.

United Kingdom National CJD Surveillance Unit - Edinburgh, Scotland, 2006. [<http://www.cjd.ed.ac.U.K./figures.htm>] - results as of Aug 4, 2006; accessed on August 14, 2006)

United Kingdom Office for National Statistics. Ninety Population Trends. Winter, 1997. [[http://www.statistics.gov.U.K./downloads/theme\\_population/PT90book\\_V2.pdf](http://www.statistics.gov.U.K./downloads/theme_population/PT90book_V2.pdf)] - Accessed on June 14, 2006]

United Kingdom Office for National Statistics, 2005 accessed at <http://statistics.gov.uk/statbase/product.asp?vlnk=1391&More=N> on Feb 2, 2005.

Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, Collinge J. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. *Lancet*. 2001 Jul 21;358(9277):171-80.

Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. *Lancet*. 347(9006):921-5.

Westat: Retroviral Epidemiological Donor Study (REDS) were obtained from Westat in Rockville, MD (2002).

World Federation of Hemophilia (WFH). June 4, 2004. (No. 5) Facts and Figures: Contract Fractionation - Revised Edition.

)



## APPENDIX A

## Supplemental technical information for the FDA Risk Assessment

The sections in this appendix provide additional technical information and details of data and modeling approaches used in specific sections (but not all sections) of Section IV. The heading and numbering of each section in this appendix mirrors the sections in "Section IV. Exposure Assessment" portion of the risk assessment.

## A- IV. A. Estimation of vCJD Prevalence in the United Kingdom (Module 1)

## A-IV. A. 3. Estimation of age-specific vCJD prevalence based on the age distribution of diagnosed vCJD cases in the UK

Cases of vCJD occur in relatively young individuals (median age of 28 years) compared to classic CJD. Blood and plasma donors are usually at the age 18-40, among whom the vCJD prevalence would be expected to be higher than the prevalence among general population. Because age specific rates of donation and vCJD infection would likely have a large effect on the final risk estimate the FDA model carefully characterizes the age specific prevalence of vCJD and donation rate. Throughout the FDA model, age specific vCJD prevalence rates are calculated for each five year age group beginning at age group of 10 – 14 yrs, 15-19 yrs and so on – and applied in estimating vCJD risk and prevalence for the residents of different geographic regions and the US blood and plasma donors who traveled to those regions. The percentage of reported vCJD cases by age is shown in Table A-4.3. The model assumes that the age-specific percentage and prevalence of incubating asymptomatic cases reflects the same age-specific trend as for reported cases of symptomatic vCJD and deaths from vCJD.

**Table A-4.3. Reported vCJD cases in the UK and percent of US Source Plasma and blood (recovered plasma) donors by age groups**

Age group	<10	10-14	15-19	18-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	>70
Reported vCJD cases in UK (through 2003) <sup>a</sup> (%)	0	5 (3.4%)	27 (18.4%)		32 (21.8%)	30 (20.4%)	22 (14.9%)	13 (8.8%)	5 (3.4%)	3 (2%)	5 (3.4%)	0 (0%)	5 (3.4%)		
Age distribution of US Source Plasma donors (%) <sup>b</sup>	0	0	0	12%	29.3%	14.1%	14.1%	9.6%	9.6%	5.8%	5.8%	0%	0%	0%	0%
Age distribution of US Blood (Recovered plasma) donors <sup>c</sup>	0	0	0	5%	13%	8%	10%	12%	13%	12%	11%	7%	4%	5%	0%

<sup>a</sup>Hilton *et al.* 2004

<sup>b</sup>Plasma Protein Therapeutics Association (Jan 07, 2005). Where data were organized in broader age group we allocated donor equally among smaller 5 year age groups

<sup>c</sup>Data provided to FDA by Westat in 2002

Some of the general variables for generating age specific estimates from the model are described below.

**Variable: *age*** - Age of vCJD cases in 5-year increments

**Variable:  $vCJD_{UK(age)}$**  - Reported vCJD cases in the UK by 5-year age groups (through 2003) beginning at 10 – 14 yrs, 15-19 yrs and so on.

**Data used in the model:** Data on the vCJD cases in the UK was derived from Hilton et al. (2004). The data includes cases through the end of 2003.

**Variable:  $Perc_{vCJD(age)}$**  - Percentage vCJD cases attributed by each age group from 10 – 14 yrs, 15-19 yrs and so on.

**Assumption used in the model:** We assume each of four age groups, 55-59 yrs, 60-64 yrs, 65-69 yrs and 70-74 yrs, contributes same percentage in vCJD cases.

For the four (five-year) age groups from 55-74yrs we assumed an equal percentage of cases were present in each of the four groups since there were very few vCJD cases in this age range. To estimate the percentages for each group we identified five reported cases (specifically, three reported cases in the age-specific prevalence grouping shown in Hilton et al. (2004) for persons aged 55-74 yrs and two cases of blood transfusion vCJD (each > 64 yrs of age) (Llewelyn 2004, Peden 2005)) in the 55-74 yr age range. The five cases in the 55-74 yr old age group are shown in Table A-4.3. We assumed an average of 1.25 cases for each of the four age groups from the ages of 55-74 yrs and divided by the total number of vCJD cases for all age groups to get the percentage of cases for each of the four sub age groups, 55-59 yrs, 60-64 yrs, 65-69 yrs and 70-74 yrs.

The percentage of vCJD cases in the UK from each age group is represented by the equation:

$$Perc_{vCJD(age)} = (vCJD_{UK(age)} / \sum_{age=0-4}^{>85} vCJD_{UK(age)}) \times 100\% \quad (IV. A. 1-1)$$

#### A-IV. A. 3. a. Estimating the UK vCJD prevalence predicted by epidemiological modeling (Clarke and Ghani 2005) for each age group

**Variable:  $vCJD_{since2002}$**  - Predicted clinical vCJD cases in the UK from 2002 onward (cases). Predicted clinical cases from 2002 onward include 32 vCJD cases diagnosed in 2002 and 2003 and 70 (95% CI of 10-190) future cases between 2004 and 2080 predicted by Clarke and Ghani (2005), which give a total of 102 cases (95% CI: 42-222 cases) after 2002.

**Variable:  $Asym-vCJD_{(age)}$**  - Number of asymptomatic vCJD infected individuals from a specific age group in year 2002.

$$Asym-vCJD_{(age)} = vCJD_{since2002} \times Perc_{vCJD(age)} \quad (IV.A.2-4)$$

**Variable:**  $Prev_{Asym-vCJD(age)}$ - Prevalence of asymptomatic vCJD infected individuals in the UK by age groups (cases/million).

The prevalence of asymptomatic vCJD cases in the UK by age group is estimated using the equation:

$$Prev_{Asym-vCJD(age)} = Asym-vCJD(age) / Pop_{UK(age)} \quad (IV.A.2-5)$$

#### A-IV. A. 3. b. Estimating the UK vCJD prevalence derived from tissue surveillance for each age group

For the risk assessment model we converted the 3 in 12,674 presumptive positive rate to an average rate of vCJD in the UK population of 1 in 4,225 (and used the 1 / 20,300 to 1 / 1,450 at 95% CI; proportions were converted from the 95% CI reported by Hilton et al (2004)). Demographic information of reported vCJD cases (Table A-4.3) indicated that the younger population (20 -29 yrs of age) that was deliberately oversampled in this study may have been more susceptible to the disease. The vCJD prevalence among UK donors might, therefore, be over-represented by the prevalence of 20-29 years age group derived from the surveillance study. Assuming the sensitivity and specificity of the testing method is 100%, the estimated rate of 1 in 4,225 translates roughly to a vCJD prevalence of 237 cases per million (95% CI: 49 – 692 cases per million) for all age groups. The authors (Hilton et al 2005) indicated that approximately 60% of the samples tested (from 7,600 patients) came from patients 20-29 years of age. Among the 20-29 year old group we calculated a vCJD prevalence of approximately 400 cases per million for which we assumed a 95% CI of 100-1200 cases per million.

We then derived the prevalences for the remainder of the UK donor population by determining the proportional difference between the vCJD prevalence from the tissue study group and the number of actual reported vCJD cases for donors in the 20-29 years age group. This proportion was then applied to the remaining age groups in the distribution of reported vCJD cases to determine the prevalence for each age group. By multiplying our extrapolated vCJD prevalence for incubating cases by the total donor population we were able to estimate the number of possible incubating vCJD cases in each US donor age group. We assumed that a plasma pool used to manufacture pdFVIII product in the US in the year 2002 consisted 6,000 to 360,000 donations, and several donations in the pool likely came from the same donor. The estimated prevalence was then used to generate variables and parameters representing the potential number of vCJD donors or donations that might be present in a plasma pool.

**Variable:**  $Prev_{Asym-vCJD(20-30)}$  Prevalence of asymptomatic vCJD infected individuals in the UK 20-30 year old age group (cases/million)

**Assumptions used in the model:** The vCJD infectious agent is present in the blood of the individual when the the accumulation of prion protein can be detected in lymphoreticular tissue. Prevalence of vCJD asymptomatic individuals in the UK 20-30 year old age group is likely to be 400 cases/million, 95% CI=100-1200 cases/million. The values for this variable were estimated from the Hilton *et al* studies (2000, 2002, 2004).

**Variable:**  $Pop_{UK(age)}$ - Population in the UK by age groups (Thousands).



**Data used in the model:** The data for UK population were sourced from UK government statistics (UK National Statistics, 2005). Where UK data were organized in broader categories of 10 to 15 years we allocated population equally among smaller 5 year age groups.

**Variable:**  $Asym-vCJD_{(20-30)}$  - The number of asymptomatic vCJD infected individuals in the 20-30 yr-old UK age group. This variable is represented by the equation:

$$Asym-vCJD_{(20-30)} = Prev_{vCJD(20-30)} \times Pop_{UK(20-30)} \quad (IV.A.2-1)$$

**Variable:**  $Asym-vCJD_{(age)}$  - Number of asymptomatic vCJD infected individuals in the UK by age groups

**Assumptions used in the model:** Number of asymptomatic vCJD infected individuals from an age group is proportional to the percentage of reported vCJD cases from that age group. The age distribution of asymptomatic vCJD cases was assumed to be the same as that of symptomatic cases.

The number of asymptomatic vCJD individuals in the UK per age group was estimated using the following equation:

$$Asym-vCJD_{(age)} = Asym-vCJD_{(20-30)} \times (Perc_{vCJD(age)} / Perc_{vCJD(20-30)}) \quad (IV.A.2-2)$$

**Variable:**  $Prev_{Asym-vCJD(age)}$  - Prevalence of asymptomatic vCJD infected individuals in the UK by age groups (cases/million).

The prevalence of asymptomatic vCJD cases in the UK by age group is estimated by the equation:

$$Prev_{Asym-vCJD(age)} = Asym-vCJD_{(age)} / Pop_{UK(age)} \quad (IV.A.2-3)$$

## A-IV. B. Estimation of vCJD Prevalence in US Plasma Donors and Plasma Pools (Module 2)

### A-IV. B. 1. a. Annual US plasma donors and characterization by age

#### A-IV. B. 1. b. Source Plasma collection in the United States: characterized by donor age

**Variable:**  $DN_S$  - Annual number of Source Plasma units used to make pdFVIII.

**Assumption used in the model:** It was assumed that, on average, 3.3 million units of Source Plasma were used in each year to make pdFVIII. It was further assumed that there is a 10% standard deviation in the number of Source Plasma units used to make pdFVIII for any given year.

**Data used in the model:** The annual number of Source Plasma units was back calculated based on annual units of pdFVIII product made from Source Plasma, the average yield of pdFVIII (187 units per liter

## APPENDIX A

plasma) and average volume of single unit of Source Plasma (700 ml per unit). The information on annual units of pdFVIII made from plasma collected in the US, yield of factor VIII and unit volume of plasma were collected from pdFVIII manufacturers.

**Variable:**  $DR_S$  – Annual number of donors who contribute Source Plasma for manufacture of pdFVIII.

**Assumption used in the model:** It was assumed that there are approximately 1 million Source Plasma donors in the US each year. It was further assumed that Source Plasma from any individual donor may be used to make pdFVIII. Therefore, we calculated that there were approximately 1 million donors who contributed Source Plasma for the manufacture of pdFVIII. It was further assumed that there could be a 10% standard deviation in the number of donors in any given year.

**Variable:** *Age* – Age information for US plasma donors was grouped in a two year increment for 18-19 years old because the model assumed that 18 was the minimum age of donation. The remaining population was grouped by 5-year increments – including 20- 24yrs old, 25-29yrs old, and so on

**Variable:**  $DR_{S-perc(age)}$  - The percentage of Source Plasma donors from a given age group.

**Data used in the model:** Distribution of US Source Plasma donors by age was obtained from the Plasma Protein Therapeutics Association (2005). Where data (PPTA, 2005) were organized in broader age groups of 10 years or 15 years, we generated 5-year age subgroups by allocating the percentage equally among each subgroup.

**Variable:**  $DR_{S(age)}$  – The annual Source Plasma donors by age groups who contribute plasma for pdFVIII manufacturing is represented by the equation:

$$DR_{S(age)} = DR_S \times DR_{S-perc(age)} \quad (IV.B.1-1)$$

#### A-IV. B. 1. c. Recovered plasma collection in the United States: Characterized by donor age

**Variable:**  $DN_R$  - Annual units of recovered plasma used to make pdFVIII.

**Assumption used in the model:** It was assumed that approximately 1,800,000 units of recovered plasma are used to make pdFVIII annually. This estimation was generated by backcalculation beginning with the total quantity of pdFVIII manufactured in the US. It was further assumed that there was a 10% standard deviation in the number of units for any given year.

**Data used in the model:** The annual number of total units of pdFVIII manufactured from recovered plasma collected in the US was estimated by back calculation. The calculation was based on the total quantity of annual units of pdVIII product made from recovered plasma collected in the US. We can further estimate the number of donations used to make the pdFVIII from recovered plasma using estimates in the literature for the average yield of pdFVIII 187 units per liter of plasma (WFH, 2004) and average volume of single unit of recovered plasma (200 ml per unit). The information on annual units of pdFVIII made from plasma collected in the US was collected from pdVIII manufacturers.

**Variable:**  $DN_{Bl-perc(age)}$  – The percentage of blood units donated by a given age group.

**Data used in the model:** Distribution of blood units by donor age group was obtained from Westat data provided to FDA in 2002 (Data shown in A-4.3).

**Variable:**  $DN_{R(age)}$  – Annual units of recovered plasma used to make pdFVIII by donor age group

$$DN_{R(age)} = DN_R \times DN_{Bl-perc(age)} \quad (IV.B.2-1)$$

**Variable:**  $DR_{R(age)}$  – Annual number of donors by age group who contribute recovered plasma that is used for manufacture of pdFVIII

**Assumption used in the model:** Each unit of recovered plasma used to make pdFVIII comes from different donors. Therefore, number of donors from an age group equals the number of donations from that age group.

The annual number of recovered plasma donors by age group was calculated using the equation:

$$DR_{R(age)} = DN_{R(age)} \quad (IV.B.2-2)$$

**Variable:**  $DR_R$  – The annual total of potential recovered plasma donors who contribute the plasma that is used for manufacture of pdFVIII, which was estimated in the model using the summation function:

$$DR_R = \sum_{age=18-19}^{70-74} DR_{R(age)} \quad (IV.B.2-3)$$

#### A-IV. B. 2. Total plasma donors and donations- for manufacture of pdFVIII in the US

**Variable:**  $DR_{Tot}$  – The annual total of potential plasma donors who contribute plasma for pdFVIII manufacturing is estimated by summing the number of Source Plasma donors and recovered plasma donors and is represented by the equation:

$$DR_{Tot} = DR_S + DR_R \quad (IV.B.3-1)$$

**Variable:**  $DN_{Tot}$  – The annual total of potential plasma units used to make pdFVIII is estimated by summing the number of Source Plasma donations and recovered plasma donations and is represented by the equation:

$$DN_{Tot} = DN_S + DN_R \quad (IV.B.3-2)$$

#### A-IV. C. Estimation of the probability that a plasma pool may contain a donation from an infected donor that contains vCJD agent